A Phase 2 interventional study of LTP001 and Placebo in Pulmonary Arterial Hypertension, sponsored by Novartis Pharmaceuticals. Terminated at 15 sites in 7 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-13.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Pulmonary Arterial Hypertension by Novartis — 1 open to participants now, 1 under way, none of them phase 3. Pulmonary Arterial Hypertension · Novartis.
Among the 12 studies in Pulmonary Arterial Hypertension by Novartis, this one is the 5th largest by enrollment, is the only one that started in 2022, is one of 5 in phase 2, and was the 10th registered.
700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →1 of the 12 studies in Pulmonary Arterial Hypertension by Novartis is open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Argentina, Australia and 15 more countries
Ages 18–100 · Healthy volunteers
By country, each count listing its studies:
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 6
First in 2006; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 47 is above the median of 40 across 478 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 27 across the 12 interventional studies. Of the 11 that completed or were terminated, 11 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Pulmonary Arterial Hypertension by Novartis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to explore the efficacy and safety of LTP001 in participants with pulmonary arterial hypertension (PAH) to determine if LTP001 had an adequate clinical profile to warrant further clinical development in this indication.
This study was a non-confirmatory, randomized, participant- and investigator-blinded, placebo controlled trial evaluating the efficacy and safety of LTP001 on top of standard of care in participants with PAH.
The study included a screening period of up to 8 weeks, followed by a 24-week treatment phase with daily dosing and visits scheduled approximately every 4 weeks. One follow-up visit, which also served as the end-of-study visit, was conducted approximately 30 days after the conclusion of the treatment phase. The total duration of the study, from the beginning of the screening period to the end-of-study visit, was approximately 37 weeks.
A total of 44 participants were planned to be randomized in a 3:1 ratio to receive either LTP001 6 mg or placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
History of PAH belonging to one of the following subgroups of the Clinical Classification Group 1 (WHO):
6MWD must be between 150 and 550 m (inclusive). The qualifying test needs to be within 20 days of randomization. To meet the above criterion additional six minute walk test (6MWT) may be performed up to a maximum of 3 tests in total prior to dosing; the minimal time difference between two tests should be at least 4 h.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received LTP001, 6 mg, oral capsules, once daily in the morning for approximately 24 weeks
Drug: LTP001
Participants received LTP001 placebo capsules matching LTP001 orally once daily in the morning for approximately 24 weeks
Drug: Placebo
LTP001, 6 mg, was administered orally once daily in the morning
Placebo to LTP001 was administered once daily in the morning
Change From Baseline in Right Heard Catheterization Pulmonary Vascular Resistance (PVR) at Week 25
PVR was defined as the resistance against blood flow from the pulmonary artery to the left atrium measured in dyn.s.cm-5
Time frame: Baseline, Week 25
Change From Baseline in Six Minute Walk Distance (6MWD)
6MWD test measures the distance that a patient can walk on a flat, hard surface in a period of 6 minutes
Time frame: Baseline, Weeks 13 and 25
Change From Baseline in Right Atrium (RA) Pressures at Week 25
The Right Heart Catheterization (RHC) assessment was performed to assess several hemodynamic variables in pulmonary hypertension, including RA pressures.
Time frame: Baseline, Week 25
Change From Baseline in Pulmonary Capillary Wedge Pressure at Week 25
Right heart catheterization (RHC) assessment was performed to assess several hemodynamic variables in pulmonary hypertension, including pulmonary capillary wedge pressure (PCWP).
Time frame: Baseline, Week 25
Change From Baseline in Mean Pulmonary Artery Pressure at Week 25
Right heart catheterization (RHC) assessment was performed to assess several hemodynamic variables in pulmonary hypertension, including pulmonary artery pressure.
Time frame: Baseline, Week 25
Change From Baseline in Average Cardiac Output (CO) at Week 25
Right heart catheterization (RHC) assessment was performed to assess several hemodynamic variables in pulmonary hypertension, including cardiac output (CO).
Time frame: Baseline, Week 25
Change From Baseline in Fractional Area Change (FAC)
Key right ventricular (RV) function endpoints such as RV fractional area change (RV FAC) were assessed with echocardiography.
Time frame: Baseline, Weeks 5, 13, and 25
Change From Baseline in Peak Velocity of Excursion (RV S')
Key right ventricular (RV) function per echocardiography. The terms Tricuspid Annular Systolic Velocity (TASV) and Peak Velocity of Excursion (RV S') are synonymous in echocardiography to describe the peak systolic velocity of the lateral tricuspid annulus. Including both TASV and RV S' as separate secondary endpoints was an oversight in the protocol as the data, calculation, and analyses for both (TASV and RV S') are identical. Therefore, the TASV and RV S' data in this results disclosure are the same.
Time frame: Baseline, Weeks 5, 13, and 25
Change From Baseline in Tricuspid Annular Plane Systolic Excursion (TAPSE)
Key right ventricular (RV) function endpoints such as tricuspid annular plane systolic excursion (TAPSE) were assessed with echocardiography.
Time frame: Baseline, Weeks 5, 13, and 25
Change From Baseline in Tricuspid Annular Systolic Velocity (TASV)
Key right ventricular (RV) function endpoints such as tricuspid annular systolic velocity (TASV) were assessed with echocardiography.
Time frame: Baseline, Weeks 5, 13 and 25
Change From Baseline in EmPHasis-10
emPHasis-10 is a questionnaire with 10 questions designed to determine how pulmonary hypertension affects a participant's life. Each item is scored on a scale of 0 to 5, with a total score ranging from 0 to 50. A higher score indicates worse quality of life.
Time frame: Baseline, Weeks 13 and 25
Change From Baseline in Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT)
PAH-SYMPACT is a questionnaire used to assess pulmonary arterial hypertension symptoms and their impact. Individual item scores range from 0 to 4. Total score is calculated as the sum of the scores for the individual items divided by the number of items. A higher score indicates more severe symptoms/impacts.
Time frame: Baseline, Weeks 13 and 25
Maximum Observed Blood Concentrations (Cmax) for LTP001
The maximum (peak) observed blood drug concentration after single dose administration.
Time frame: Day 1 and Week 25 at 15, 45, and 120 minutes post-dose
Time to Reach Maximum Blood Concentrations (Tmax) of LTP001
The time to reach maximum (peak) blood drug concentration after single dose administration.
Time frame: Day 1 and Week 25 at 15, 45, and 120 minutes post-dose
Time to Clinical Worsening
Time to any of the following: * Death * Hospital stay greater than 24 hours due to worsening of pulmonary arterial hypertension * Worsening of PAH resulting in need for lung transplantation or balloon atrial septostomy * Initiation of parenteral prostanoid therapy, initiation of oxygen therapy, initiation of any other pulmonary arterial hypertension-specific therapies or need for increase of diuretics for more than 4 weeks due to worsening of pulmonary arterial hypertension * Significant drop in six minute walk distance
Time frame: Baseline up to approximately 30 weeks
Change From Baseline in N-terminal Fragment of the Prohormone B-type Natriuretic Peptide (NT-ProBNP)
NT-proBNP is a blood biomarker to assess right ventricular distress.
Time frame: Baseline to Week 29
| Milestone | LTP001 | Placebo |
|---|---|---|
| Started | 35 | 12 |
| Completed | 26 | 9 |
| Not completed | 9 | 3 |
| Withdrew: Adverse event | 2 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Study terminated by sponsor | 6 | 3 |
PVR was defined as the resistance against blood flow from the pulmonary artery to the left atrium measured in dyn.s.cm-5
| dynes.sec.cm^-5 | LTP001 | Placebo |
|---|---|---|
| Change From Baseline in Right Heard Catheterization Pulmonary Vascular Resistance (PVR) at Week 25 | -1.175 ± 254.0792 | -49.685 ± 181.3745 |
6MWD test measures the distance that a patient can walk on a flat, hard surface in a period of 6 minutes
| meters | LTP001 | Placebo |
|---|---|---|
| Week 13 n=30,10 | 3.2 ± 42.45 | 7.4 ± 29.34 |
| Week 25 n=28,10 | 10.4 ± 44.36 | 21.0 ± 32.33 |
The Right Heart Catheterization (RHC) assessment was performed to assess several hemodynamic variables in pulmonary hypertension, including RA pressures.
| mmHg | LTP001 | Placebo |
|---|---|---|
| Change From Baseline in Right Atrium (RA) Pressures at Week 25 | -0.4 ± 4.40 | -0.6 ± 0.73 |
Right heart catheterization (RHC) assessment was performed to assess several hemodynamic variables in pulmonary hypertension, including pulmonary capillary wedge pressure (PCWP).
| mmHg | LTP001 | Placebo |
|---|---|---|
| Change From Baseline in Pulmonary Capillary Wedge Pressure at Week 25 | 0.2 ± 3.66 | 0.9 ± 2.26 |
Right heart catheterization (RHC) assessment was performed to assess several hemodynamic variables in pulmonary hypertension, including pulmonary artery pressure.
| mmHg | LTP001 | Placebo |
|---|---|---|
| Change From Baseline in Mean Pulmonary Artery Pressure at Week 25 | 0.4 ± 8.55 | -0.6 ± 5.61 |
Right heart catheterization (RHC) assessment was performed to assess several hemodynamic variables in pulmonary hypertension, including cardiac output (CO).
| liters per minute | LTP001 | Placebo |
|---|---|---|
| Change From Baseline in Average Cardiac Output (CO) at Week 25 | 0.067 ± 1.0772 | 0.493 ± 0.9075 |
Key right ventricular (RV) function endpoints such as RV fractional area change (RV FAC) were assessed with echocardiography.
| percent | LTP001 | Placebo |
|---|---|---|
| Week 5 n=31,9 | 0.35 ± 6.944 | 0.92 ± 5.622 |
| Week 13 n=29,10 | -1.19 ± 6.424 | 2.62 ± 4.417 |
| Week 25 n=26,8 | -1.85 ± 5.412 | -1.45 ± 7.532 |
Key right ventricular (RV) function per echocardiography. The terms Tricuspid Annular Systolic Velocity (TASV) and Peak Velocity of Excursion (RV S') are synonymous in echocardiography to describe the peak systolic velocity of the lateral tricuspid annulus. Including both TASV and RV S' as separate secondary endpoints was an oversight in the protocol as the data, calculation, and analyses for both (TASV and RV S') are identical. Therefore, the TASV and RV S' data in this results disclosure are the same.
| centimeters per second | LTP001 | Placebo |
|---|---|---|
| Week 5 n=33,11 | 0.2 ± 2.14 | -0.4 ± 1.50 |
| Week 13 n=32,11 | -0.2 ± 2.38 | -0.5 ± 1.63 |
| Week 25 n=26,9 | 0.4 ± 2.28 | -1.0 ± 3.00 |
Key right ventricular (RV) function endpoints such as tricuspid annular plane systolic excursion (TAPSE) were assessed with echocardiography.
| centimeters | LTP001 | Placebo |
|---|---|---|
| Week 5 n=33,11 | 0.061 ± 0.3181 | 0.042 ± 0.3383 |
| Week 13 n=31,11 | -0.026 ± 0.2594 | 0.100 ± 0.2933 |
| Week 25 n=27,9 | 0.015 ± 0.3697 | -0.067 ± 0.2121 |
Key right ventricular (RV) function endpoints such as tricuspid annular systolic velocity (TASV) were assessed with echocardiography.
| centimeters per second | LTP001 | Placebo |
|---|---|---|
| Week 5 n=33,11 | 0.2 ± 2.14 | -0.4 ± 1.50 |
| Week 13 n=32,11 | -0.2 ± 2.38 | -0.5 ± 1.63 |
| Week 25 n=26,9 | 0.4 ± 2.28 | -1.0 ± 3.00 |
emPHasis-10 is a questionnaire with 10 questions designed to determine how pulmonary hypertension affects a participant's life. Each item is scored on a scale of 0 to 5, with a total score ranging from 0 to 50. A higher score indicates worse quality of life.
| score | LTP001 | Placebo |
|---|---|---|
| Week 13 n=21,9 | -1.490 ± 5.7108 | -3.622 ± 3.1712 |
| Week 25 n=17,9 | -4.972 ± 8.7643 | -3.000 ± 4.2961 |
PAH-SYMPACT is a questionnaire used to assess pulmonary arterial hypertension symptoms and their impact. Individual item scores range from 0 to 4. Total score is calculated as the sum of the scores for the individual items divided by the number of items. A higher score indicates more severe symptoms/impacts.
| score | LTP001 | Placebo |
|---|---|---|
| Week 13 | -1.452 ± 6.3897 | -3.545 ± 3.2693 |
| Week 25 | -0.680 ± 5.7304 | -4.220 ± 6.1990 |
The maximum (peak) observed blood drug concentration after single dose administration.
| ng/mL | LTP001 | Placebo |
|---|---|---|
| Day 1 | 38.6 ± 58.2 | — |
| Week 25 | 39.2 ± 54.7 | — |
The time to reach maximum (peak) blood drug concentration after single dose administration.
| hours | LTP001 | Placebo |
|---|---|---|
| Day 1 | 1.05 ± 56.6 | — |
| Week 25 | 0.979 ± 68.8 | — |
Time to any of the following: * Death * Hospital stay greater than 24 hours due to worsening of pulmonary arterial hypertension * Worsening of PAH resulting in need for lung transplantation or balloon atrial septostomy * Initiation of parenteral prostanoid therapy, initiation of oxygen therapy, initiation of any other pulmonary arterial hypertension-specific therapies or need for increase of diuretics for more than 4 weeks due to worsening of pulmonary arterial hypertension * Significant drop in six minute walk distance
| days | LTP001 | Placebo |
|---|---|---|
| Time to Clinical Worsening | 211.0 (174.0 to NA) | 175.0 (174.0 to NA) |
NT-proBNP is a blood biomarker to assess right ventricular distress.
| picomoles per liter | LTP001 | Placebo |
|---|---|---|
| Change From Baseline in N-terminal Fragment of the Prohormone B-type Natriuretic Peptide (NT-ProBNP) | 4.609 ± 52.9047 | -7.918 ± 21.9731 |
Collected over Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 241 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LTP001 | 0/35 (0%) | 5/35 (14.3%) | 20/35 (57.1%) |
| Placebo | 0/12 (0%) | 2/12 (16.7%) | 7/12 (58.3%) |
| Total | 0/47 (0%) | 7/47 (14.9%) | 27/47 (57.4%) |
| Event | LTP001 | Placebo | Total |
|---|---|---|---|
| Abdominal pain upperGastrointestinal disorders | 0/35 | 1/12 | 1/47 |
| Catheter site cellulitisInfections and infestations | 0/35 | 1/12 | 1/47 |
| Right ventricular failureCardiac disorders | 1/35 | 0/12 | 1/47 |
| DiarrhoeaGastrointestinal disorders | 1/35 | 0/12 | 1/47 |
| VomitingGastrointestinal disorders | 1/35 | 0/12 | 1/47 |
| COVID-19Infections and infestations | 1/35 | 0/12 | 1/47 |
| Lower respiratory tract infectionInfections and infestations | 1/35 | 0/12 | 1/47 |
| Bipolar disorderPsychiatric disorders | 1/35 | 0/12 | 1/47 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 1/35 | 0/12 | 1/47 |
| Pulmonary arterial hypertensionRespiratory, thoracic and mediastinal disorders | 1/35 | 0/12 | 1/47 |
| Event | LTP001 | Placebo | Total |
|---|---|---|---|
| HeadacheNervous system disorders | 6/35 | 0/12 | 6/47 |
| NauseaGastrointestinal disorders | 4/35 | 1/12 | 5/47 |
| PalpitationsCardiac disorders | 3/35 | 1/12 | 4/47 |
| InfluenzaInfections and infestations | 3/35 | 0/12 | 3/47 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/35 | 0/12 | 3/47 |
| Iron deficiency anaemiaBlood and lymphatic system disorders | 0/35 | 1/12 | 1/47 |
| TachycardiaCardiac disorders | 0/35 | 1/12 | 1/47 |
| VomitingGastrointestinal disorders | 1/35 | 1/12 | 2/47 |
| Chest discomfortGeneral disorders and administration site conditions | 0/35 | 1/12 | 1/47 |
| FatigueGeneral disorders and administration site conditions | 2/35 | 1/12 | 3/47 |
| Age, Continuous(Years) | LTP001 | Placebo | Total |
|---|---|---|---|
| Mean | 45.3 ± 13.03 | 45.3 ± 13.78 | 45.3 ± 13.07 |
| Age, Customized(Participants) | LTP001 | Placebo | Total |
|---|---|---|---|
| 18 - <65 | 32 | 11 | 43 |
| 65 - <85 | 3 | 1 | 4 |
| Sex: Female, Male(Participants) | LTP001 | Placebo | Total |
|---|---|---|---|
| Female | 29 | 10 | 39 |
| Male | 6 | 2 | 8 |
| Race/Ethnicity, Customized(Participants) | LTP001 | Placebo | Total |
|---|---|---|---|
| White | 32 | 11 | 43 |
| American Indian or Alaska | 2 | 0 | 2 |
| Asian | 1 | 1 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Jun 2022 to primary completion in Mar 2024, 20 months.
Results were first posted in May 2025, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: LTP001
Pulmonary Arterial Hypertension →